XML 18 R6.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Operating activities:      
Net loss $ (227,278,000) $ (204,749,000) $ (178,840,000)
Adjustments to reconcile net loss to net cash used for operating activities:      
Stock-based compensation expense 50,218,000 51,411,000 33,367,000
Depreciation and amortization 2,847,000 2,044,000 1,513,000
Amortization of debt discount 1,429,000 1,050,000 890,000
Amortization of premium (accretion of discount) on short-term investments 125,000 (3,730,000) (3,412,000)
Realized gain on available-for-sale investments 0 (8,000) 0
Impairment of property and equipment 847,000 107,000 72,000
Loss on disposal of property and equipment   62,000 29,000
Change in operating assets and liabilities:      
Accounts receivable (1,971,000) 24,773,000 (22,778,000)
Inventory (16,937,000) 14,064,000 (29,122,000)
Prepaid expenses and other assets 1,295,000 (12,052,000) (7,482,000)
Accounts payable (2,233,000) (14,105,000) (1,906,000)
Accrued clinical and manufacturing liabilities 15,348,000 10,144,000 (3,614,000)
Accrued payroll and employee liabilities (1,651,000) 1,851,000 4,537,000
Other accrued liabilities (6,859,000) 4,558,000 14,941,000
Net cash used for operating activities (184,820,000) (124,580,000) (191,805,000)
Investing activities:      
Purchases of short-term investments (134,007,000) (477,035,000) (497,104,000)
Maturities and sales of short-term investments 349,775,000 462,406,000 227,700,000
Purchases of property and equipment (6,813,000) (7,154,000) (9,171,000)
Proceeds from the sale of property and equipment     25,000
Net cash provided by (used for) investing activities 208,955,000 (21,783,000) (278,550,000)
Financing activities:      
Net proceeds from sale of common stock and/or pre-funded warrants   162,151,000 363,128,000
Proceeds from purchases under the Employee Stock Purchase Plan 2,317,000 2,109,000 1,179,000
Proceeds from stock option exercises 6,759,000 22,164,000 18,301,000
Proceeds from conversion of convertible notes payable 26,000    
Proceeds from warrant exercises 3,000 1,000  
Repayment of promissory note payable to related party     (25,000,000)
Net cash provided by financing activities 9,105,000 186,425,000 357,608,000
Net increase (decrease) in cash and cash equivalents 33,240,000 40,062,000 (112,747,000)
Cash and cash equivalents at beginning of year 71,898,000 31,836,000 144,583,000
Cash and cash equivalents at end of year $ 105,138,000 $ 71,898,000 31,836,000
Supplemental disclosure of cash flow information:      
Interest paid     1,183,000
Cumulative effect of adoption of new accounting standard     $ 1,574,000